L’Alliance Promotion Microbiote présente les résultats de la première étude sur l’industrie du microbiote en…
MaaT PharmaOctober 11, 2021
MaaT Pharma awarded non-dilutive funding of EURO 1.9 million for its “MEPA” project through the…
MaaT PharmaJuly 20, 2021
Independent Data Safety and Monitoring Board (DSMB) recommends continuing study as planned and initiating dosing…
MaaT PharmaJune 28, 2021
The trial of the autologous microbial therapy, MaaT011, met its primary endpoints through demonstration of…
MaaT PharmaMay 25, 2021
L'essai de la thérapie autologue de restauration du microbiote, MaaT011, a atteint ses objectifs principaux…
MaaT PharmaMay 25, 2021
Communiqué de presse Lancement de l’Alliance Promotion Microbiote Le 29 mars 2021 – L’Alliance Promotion…
MaaT PharmaMarch 29, 2021
Study meets primary and key secondary objectives with positive impact and favorable overall safety profile…
MaaT PharmaMarch 17, 2021
Data from 29 patients in the company’s early access program with MaaT013 as a treatment…
MaaT PharmaMarch 11, 2021
Independent Data Safety and Monitoring Board (DSMB) recommends continuing CIMON study and initiating dosing of…
MaaT PharmaDecember 22, 2020
